Frontiers | Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
iLLUMINATE - Progression-Free Survival | IMBRUVICA® (ibrutinib) HCP
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
PDF) Management of front line chronic lymphocytic leukemia
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
PCYC 2014.12.31 - 10-K
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
Visual abstract | Final analysis of the phase III iLLUMINATE trial in patients with CLL/SLL
Data Presented at ASH 2018 Provide Evidence of First-line Treatment Benefits with IMBRUVICA®▽ (ibrutinib)-Based Therapy Across All Patient Populations in CLL | Business Wire
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
IMBRUVICA® IN chronic lymphocytic leukaemia (CLL): experience you can rely on<sup>1-5</sup>
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | SpringerLink
Progression-free survival and overall survival for ibrutinib and... | Download Scientific Diagram
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
Folie 1
